QuiremScout^™ awarded top 3 most innovative medical device in the 2019 Belgian Galenus prize

09/12/2020 – LEUVEN, BELGIUM

Quirem Medical, a Terumo company, is awarded top 3 innovative medical device in the 2019 Belgian Galenus prize with the innovative Holmium-166 SIRT diagnostic scout dose product QuiremScout^™.

The Galenus prize recognizes and rewards outstanding achievements that improve the global human condition through the development of innovative therapies¹. It was created in France in 1970 by a pharmacist named Roland Mehl with the aim to advance pharmaceutical research. Recently, the Prix Galien award is also granted to innovative medical devices.²

The role of QuiremScout^™ microspheres is to evaluate the expected safety and efficacy of the Selective Internal Radiation Therapy (SIRT). QuiremScout^™ microspheres are based on the same Holmium-166 microspheres as the therapeutic treatment (QuiremSpheres^™). QuiremScout^™ microspheres are intended to evaluate lung-shunt³ and extrahepatic deposition³ as part of the SIRT work-up. Moreover, they are intended for evaluation of the intrahepatic distribution³ during the work-up, which can be used to plan the SIRT treatment.⁴

Currently, ^99mTc-MAA is most often used during the pre-treatment work-up of the SIRT treatment algorithm³.

However, QuiremScout^™ has recently proven to be more accurate in terms of intrahepatic targeting⁵ and lung shunt assessment⁶ compared to ^99mTc-MAA during the work-up. The usage of QuiremScout^™ microspheres may allow physicians to improve their SIRT treatment planning.³

Recent clinical results continue to support the validation of QuiremScout^™ microspheres in patient selection and planning as part of the Holmium Platform, such as the latest publication in the Lancet Oncology Journal from UMC Utrecht for the non-randomized HEPAR PLuS study⁷, which included Neuroendocrine tumor (NET) patients with liver metastasis after systemic radiation therapy with ¹⁷⁷Lu-Dotatate.

The Holmium platform consists of three integrated products (QuiremScout^™, QuiremSpheres^™ & Q-suite^™), which equips physicians with the necessary tools to optimize SIRT outcomes through more individualized treatment.

“QuiremScout is part of the Holmium platform that enables physicians to perform Selective intra-arterial radiation therapy. This technology uniquely allows a fine patient selection and individualized treatment for better outcomes. At Terumo, we are proud of this important recognition by the community.”, said Laurent Domas, Vice President Global Interventional Oncology & Therapy Development, Terumo Interventional Systems.

Learn more about SIRT, the Holmium Platform and how patients with non-resectable liver disease may benefit from QuiremScout^™ microspheres.

https://www.terumo-europe.com/en-emea/products/quiremspheres%C2%AE-microspheres#Deroose

References:
https://www.prixgalien.nl/
http://www.prixgalien-galenusprijs.be/
Instructions for Use- QuiremScout^™ (rev 05)
Chiesa & Maccauro, 2020 EJNMM
Smits et al., 2019 EJNMM
Elschot et al., 2014 EJNMM
Braat et. Al. 2020, Lancet Oncology